io,
Kidneys end up impaired with diabetes - especially serious insulin-resistant cases. If Iplex had reversed problems with glomerular filtration or albumin excretion in just 7 days at a dose lower than the minimum approved starting dose for Iplex (for the IGFD indication) that would have been a home run.
One doesn't expect home runs in short studies in complex chronic diseases. Iplex may or may not effect GFR or microalbuminuria on a longer treatment with higher doses. We won't know unless someone decides to do a longer study at higher doses in more patients.
Still, this small study adds another confirmation that Iplex has real insulin sensitizing effects (no surprise since IGF-1 should do this). Lends credence to Iplex's therapeutic potential as an adjunct treatment in Severely Insulin Resistant (SIR) diabetics.
I've not seen any data from Tercica on this. Another example where Insmed is supporting Iplex development along multiple lines, while Tercica seems like a johnny one-note act.
Anyway, this supports Insmed's statements that SIR diabetes is a legit development target for Iplex.
cheers
News 
Market Data 
Discover 
